Brady Martz Wealth Solutions LLC Invests $1.52 Million in Pfizer Inc. (NYSE:PFE)

Brady Martz Wealth Solutions LLC has taken a significant step by purchasing a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter. According to the company’s latest Form 13F filing with the SEC, this institutional investor acquired 57,714 shares of Pfizer's stock, which amounts to a total investment of approximately $1,524,000.

Other institutional investors have also adjusted their investments in Pfizer. Retirement Wealth Solutions LLC bought a new position in the company valued at around $26,000 during the same quarter. Meanwhile, Gladius Capital Management LP increased its position in Pfizer by a remarkable 102.8% in the 3rd quarter, bringing their total holdings to 1,043 shares, valued at $30,000 after acquiring an additional 38,015 shares. Quarry LP and Teachers Insurance & Annuity Association of America both made new investments in Pfizer during previous quarters, valued at $31,000 and $35,000 respectively. Furthermore, Joseph Group Capital Management boosted its holdings in Pfizer by 168.3%, owning 1,229 shares valued at $36,000 after buying an additional 771 shares in the last quarter. Collectively, institutional investors hold a substantial 68.36% of the total shares in the company.

Wall Street Analysts Forecast Growth

Recent reports from several equities analysts regarding Pfizer (PFE) indicate a variety of perspectives. StockNews.com lowered its rating from "strong-buy" to "buy" on November 20th. Sanford C. Bernstein started covering Pfizer on October 17th, issuing a 'market perform' rating with a target price of $32.00. Conversely, Wolfe Research began coverage with an "underperform" rating and set a price target of $25.00. Evercore ISI upgraded Pfizer to a "strong-buy" rating on October 30th, while Citigroup assigned a "neutral" rating and a $30.00 target price on October 25th. In total, one analyst has issued a sell rating, eight have assigned a hold rating, six have given a buy rating, and two have awarded a strong buy rating, leading to an average rating of "Moderate Buy" with an average target price of $32.00 according to MarketBeat.com.

Pfizer Stock Down 0.7%

As of Friday, shares of Pfizer opened at $26.30. Over the past year, the stock has traded between a low of $24.48 and a high of $31.54. Current financials indicate a current ratio of 1.00, a quick ratio of 0.73, and a debt-to-equity ratio of 0.63. Pfizer's market capitalization currently stands at $149.06 billion, with a P/E ratio of 35.55 and a price-to-earnings growth rate of 0.64. The stock’s 50-day moving average is $26.08, while the 200-day moving average is $27.99.

Pfizer's Recent Earnings Report

On October 29th, Pfizer announced its quarterly earnings, revealing earnings per share (EPS) of $1.06, which surpassed consensus estimates of $0.64 by $0.42. Company revenue reached $17.70 billion, exceeding the expected revenue of $14.92 billion. Pfizer reported a net margin of 7.07% and a return on equity of 16.28%, marking a year-over-year revenue increase of 31.2%. Analysts predict that the company will post an EPS of 2.94 for the current fiscal year.

Increased Dividend Announcement

Pfizer recently declared a quarterly dividend, set to be paid on March 7th. Investors who hold shares by January 24th will receive a $0.43 dividend. The ex-dividend date is the same day. This change raises the annualized dividend to $1.72, providing an attractive yield of 6.54%, up from the previous quarterly dividend of $0.42. Notably, Pfizer's dividend payout ratio (DPR) is currently high at 232.43%.

Insider Activity

In related news, Pfizer's director Scott Gottlieb recently purchased 1,000 shares on October 30th at an average price of $28.24 each, totaling $28,240. After the purchase, he holds 10,000 shares in Pfizer, valued at $282,400—a significant increase in his ownership by 11.11%. This transaction was disclosed in documents filed with the SEC.

About Pfizer

Pfizer Inc. is involved in the discovery, development, manufacturing, marketing, and distribution of biopharmaceutical products across the globe. The company offers a range of medicines and vaccines addressing various health areas, including cardiovascular, infectious diseases, and COVID-19 prevention and treatment. Some of its well-known products include Comirnaty and Paxlovid.

investment, shares, Pfizer